Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.54 |
| ▸ | PLAU | P00749 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.50 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.50 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3193186 | 0.85 | MAPK14 (0.61) | KMT2AMAPK14HDAC6HDAC1HDAC2 | |
| SCHEMBL29509279 | 0.84 | HTR6 (0.73) | HTR6KMT2APLAUHDAC6HDAC1 | |
| SCHEMBL31021 | 0.84 | HTR6 (0.73) | HTR6KMT2APLAUHDAC6HDAC1 | |
| SCHEMBL18284227 | 0.83 | ALOX5 (0.59) | HTR6KMT2AMAPK14NPC1RAB9A | |
| SCHEMBL6086767 | 0.82 | MAPK14 (0.54) | HTR6KMT2AMAPK14NPSR1ALOX5 | |
| SCHEMBL6100496 | 0.82 | ALOX5 (0.61) | KMT2AMAPK14NPC1RAB9AMEN1 | |
| SCHEMBL6086123 | 0.82 | MAPK14 (0.54) | KMT2AMAPK14NPC1RAB9AMEN1 | |
| SCHEMBL24414699 | 0.82 | MAOB (0.56) | HTR6MAPK14KDM4EALDH1A1ALOX5 | |
| SCHEMBL30991821 | 0.82 | MAOB (0.56) | HTR6MAPK14KDM4EALDH1A1ALOX5 | |
| SCHEMBL6086778 | 0.81 | HTR6 (0.66) | HTR6KMT2APLAUHDAC6HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1244652-B1 | 2-(1H-INDOL-3-YL)-2-OXO-ACETAMIDES WITH ANTITUMOR ACTIVITY | CELL THERAPEUTICS EUROPE SRL (IT) | 2005-08-24 | — | — | EP | disclosed |
| US-6753342-B2 | ANTICARCINOGENIC AGENTS FOR LUNG AND COLON CANCER TREATMENT | NOVUSPHARMA S.P.A. (IT) | 2004-06-22 | — | — | US | disclosed |
| US-20030158153-A1 | 2-(1h-indol-3-yl)-2-oxo-acetamides containing a thiophene or furan ring; anticarcinogenic agents particular against solid tumors of colon and lung | NOVUSPHARMA S.P.A. (IT) | 2003-08-21 | — | — | US | disclosed |
| EP-1244652-A1 | 2-(1H-INDOL-3-YL)-2-OXO-ACETAMIDES WITH ANTITUMOR ACTIVITY | Cell Therapeutics Europe S.R.L. (IT) | 2002-10-02 | — | — | EP | disclosed |
| WO-2001047916-A1 | 2-(1H-INDOL-3-YL)-2-OXO-ACETAMIDES WITH ANTITUMOR ACTIVITY | NOVUSPHARMA S.P.A. (IT) | 2001-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158153-A1 | 2-(1h-indol-3-yl)-2-oxo-acetamides containing a thiophene or furan ring; anticarcinogenic agents particular against solid tumors of colon and lung | IDO2, IDO1, TXNRD2 | HTR6 2619/4885KMT2A 1607/4885MAPK14 3635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.